Albany, NY -- (SBWIRE) -- 04/23/2019 -- Lupus Nephritis - Epidemiology and Market Forecast-2028

Lupus nephritis is clinically evident in 50-60% of patients with systemic lupus erythematosus (SLE)

1. Lupus Nephritis is a major risk factor for morbidity and mortality in SLE.
2. Lupus nephritis is a common complication of young female patients with SLE, and the most prevalent etiology of secondary glomerular diseases.
3. 10% of patients with Lupus nephritis will develop End-stage Renal Disease.

DelveInsight launched a new report Lupus Nephritis Market Insights, Epidemiology and Market Forecast-2028

Request for sample pages

Key benefits

1. Lupus Nephritis market report covers a descriptive overview and comprehensive insight of the Lupus Nephritis epidemiology and Lupus Nephritis market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Lupus Nephritis market report provides insights on the current and emerging therapies.
3. Lupus Nephritis Dystrophy market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Lupus Nephritis market report provides an edge that will help in developing business strategies, by understanding trends shaping and driving the Lupus Nephritis market.

"Lupus Nephritis treatment consists of two phases - induction and maintenance."

Induction therapy refers to the initial therapeutic regimen given in an attempt to produce remission of active disease. The induction phase is followed by a maintenance phase to sustain remission over a long period of time and to prevent disease flare.

Various therapies have been studied for maintenance therapy, including azathioprine, MMF, and cyclophosphamide, all combined with corticosteroids.

Lupus Nephritis market is expected to experience positive growth in the coming years owing to the launch of distinctive emerging therapies in the coming years. Additionally, due to the lack of therapies which effectively stop or slow the disease progression a potential opportunity exists for the development and launch of novel therapies.

Major pharmaceutical companies, such as

1. Aurinia Pharmaceuticals
2. Roche
3. AstraZeneca
4. Novartis
5. Boehringer Ingelheim
and many others.

Drugs that are involved are
1. Obinutuzumab
2. Voclosporin
3. Anifrolumab
4. CFZ533
5. BI 655064
And many others

Table of contents

1. Report Introduction
2. Lupus Nephritis Market Overview at a Glance
3. Lupus Nephritis Disease Background and Overview
4. Lupus Nephritis Epidemiology and Patient Population
5. Lupus Nephritis Epidemiology by Countries (2017-2028)
5.1. United States- Epidemiology (2017-2028)
5.2. EU-5 Epidemiology (2017-2028)
5.3. Germany-Epidemiology (2017-2028)
5.4. France-Epidemiology (2017-2028)
5.5. Italy-Epidemiology (2017-2028)
5.6. Spain-Epidemiology (2017-2028)
5.7. United Kingdom-Epidemiology (2017-2028)
5.8. Japan-Epidemiology (2017-2028)
6. Lupus Nephritis Treatments & Medical Practices
7. Emerging Therapies
7.1. Key Cross Competition
7.2. Voclosporin: Aurinia Pharmaceuticals
7.3. Obinutuzumab: Roche
7.4. Anifrolumab: AstraZeneca
8. Lupus Nephritis Market Size
9. 7MM Country-Wise Market Analysis
9.1. United States Market Size
9.2. Germany Market Size
9.3. France Market Size
9.4. Italy Market Size
9.5. Spain Market Size
9.6. United Kingdom Market Size
9.7. Japan Market Size
10. Market Drivers
11. Market Barriers
12. Report Methodology
13. DelveInsight Capabilities
14. Disclaimer
15. About DelveInsight

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:
Shruti Thakur
info@delveinsight.com
+919650213330
SOURCE DelveInsight